Online inquiry

IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ2248MR)

This product GTTS-WQ2248MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 1 & N1-Methylpseudo-UTP. It ecodes the monoclonal antibody that targets F gene. The antibody can be applied in Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Infection (LRTI) research.
Specifications
Product type mRNA
Modified bases N1-Methylpseudo-UTP
5' Cap Cap 1
Species Lama glama
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
UniProt ID P03420
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-F, ALX-0171(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) (GTTS-WQ2248MR). Click the button above to contact us or submit your feedback about this product.

See other products
CAT Product Name Product Type CDs
GTTS-WQ10732MR IVTScrip™ mRNA-Anti-FCGRT, M-281(Cap 0, Pseudo-UTP, 30 nt-poly(A)) mRNA M-281
GTTS-WQ11464MR IVTScrip™ mRNA-Anti-ERBB3, MEHD7945A(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA MEHD7945A
GTTS-WQ8357MR IVTScrip™ mRNA-Anti-MUC1, hPAM4(Cap 0, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA hPAM4
GTTS-WQ4902MR IVTScrip™ mRNA-Anti-ACVR2, BYM338(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA BYM338
GTTS-WQ11899MR IVTScrip™ mRNA-Anti-CCR2, MLN-1202(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA MLN-1202
GTTS-WQ11858MR IVTScrip™ mRNA-Anti-TIGIT, MK-7684(Cap 1, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA MK-7684
GTTS-WQ69MR IVTScrip™ mRNA-Anti-H1-0, (131)I-chTNT-1/B(Cap 0, 5-Methoxy-UTP, 30 nt-poly(A)) mRNA (131)I-chTNT-1/B
GTTS-WQ1700MR IVTScrip™ mRNA-Anti-Dabigatran, aDabi-Fab(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA aDabi-Fab
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW